C3N-04173
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 69.99041752
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ANGIOGENESIS+0.400
- COAGULATION+0.390
- CHOLESTEROL_HOMEOSTASIS+0.360
- TNFA_SIGNALING_VIA_NFKB+0.360
- ESTROGEN_RESPONSE_EARLY+0.330
- FATTY_ACID_METABOLISM+0.330
- MYOGENESIS+0.310
- PANCREAS_BETA_CELLS+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V2-0.490
- MITOTIC_SPINDLE-0.340
- MYC_TARGETS_V1-0.330
- INTERFERON_ALPHA_RESPONSE-0.320
- SPERMATOGENESIS-0.270
- DNA_REPAIR-0.240
- PI3K_AKT_MTOR_SIGNALING-0.240
- INTERFERON_GAMMA_RESPONSE-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613755 | — | F | 0.886 |
| 2 | TCGA-AN-A03X-01A-21R-A00Z-07 | — | A | 0.886 |
| 3 | SRR8518353 | — | F | 0.877 |
| 4 | SRR8518203 | — | A | 0.872 |
| 5 | TCGA-BH-A0HI-01A-11R-A084-07 | — | B | 0.870 |
| 6 | 20060059.TNBC | — | F | 0.869 |
| 7 | MBCproject_0031_T1_RNA | — | A | 0.867 |
| 8 | MNG329 | — | — | 0.866 |
| 9 | TCGA-CV-7411-01A-11R-2081-07 | — | — | 0.862 |
| 10 | 20020085.TNBC | — | F | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |